×
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80

Design Therapeutics Stock Forecast, Price & News

$14.66
+0.36 (+2.52%)
(As of 07/6/2022 05:43 PM ET)
Add
Compare
Today's Range
$13.85
$14.91
50-Day Range
$9.91
$16.26
52-Week Range
$9.61
$22.20
Volume
302,428 shs
Average Volume
244,892 shs
Market Capitalization
$817.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00

Design Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
29.6% Upside
$19.00 Price Target
Short Interest
Bearish
13.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.09) to ($1.54) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.94 out of 5 stars

Medical Sector

549th out of 1,433 stocks

Pharmaceutical Preparations Industry

264th out of 683 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive DSGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Design Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Design Therapeutics

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

DSGN Stock News Headlines

Design Therapeutics (NASDAQ:DSGN) Shares Gap Up to $14.99
EGIO, AMED and HUMA among hour after mover.
DSGN Design Therapeutics, Inc.
4 Analysts Have This to Say About Design Therapeutics
Wednesday 3/23 Insider Buying Report: DSGN
Design Therapeutics GAAP EPS of -$0.20
Design Therapeutics, Inc. (DSGN)
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DSGN
Fax
N/A
Employees
37
Year Founded
N/A

Company Calendar

Last Earnings
5/09/2022
Today
7/07/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$19.00
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+29.6%
Consensus Rating
Hold
Rating Score (0-4)
2.33333333333333
Research Coverage
3 Analysts

Profitability

Net Income
$-35,530,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$230,000.00
Book Value
$6.87 per share

Miscellaneous

Free Float
41,446,000
Market Cap
$817.73 million
Optionable
Not Optionable
Beta
1.23














Design Therapeutics Frequently Asked Questions

Should I buy or sell Design Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Design Therapeutics in the last year. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Design Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DSGN, but not buy additional shares or sell existing shares.
View analyst ratings for Design Therapeutics
or view top-rated stocks.

What is Design Therapeutics' stock price forecast for 2022?

3 equities research analysts have issued twelve-month price targets for Design Therapeutics' stock. Their DSGN stock forecasts range from $6.00 to $30.00. On average, they predict Design Therapeutics' share price to reach $19.00 in the next twelve months. This suggests a possible upside of 29.6% from the stock's current price.
View analysts' price targets for Design Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Design Therapeutics' stock price performed in 2022?

Design Therapeutics' stock was trading at $21.41 at the start of the year. Since then, DSGN stock has decreased by 31.5% and is now trading at $14.66.
View the best growth stocks for 2022 here
.

When is Design Therapeutics' next earnings date?

Design Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Design Therapeutics
.

How were Design Therapeutics' earnings last quarter?

Design Therapeutics, Inc. (NASDAQ:DSGN) posted its quarterly earnings data on Monday, May, 9th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.02.
View Design Therapeutics' earnings history
.

Who are Design Therapeutics' key executives?

Design Therapeutics' management team includes the following people:
  • Dr. João Siffert M.D., Pres, CEO & Director (Age 59, Pay $993k)
  • Dr. Sean Jeffries Ph.D., Chief Operating Officer (Age 42, Pay $476k)
  • Dr. Aseem Z. Ansari Ph.D., Co-Founder & Scientific Advisor
  • Ms. Julie D. Burgess CPA, Chief Accounting Officer
  • Dr. Elizabeth Gordon Ph.D., Sr. VP of Regulatory Affairs
  • Dr. Jae B. Kim FACC, M.D., Chief Medical Officer (Age 52)
  • Ms. Dawn Giangiulio, Controller

When did Design Therapeutics IPO?

(DSGN) raised $228 million in an IPO on Friday, March 26th 2021. The company issued 12,000,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, SVB Leerink and Piper Sandler acted as the underwriters for the IPO.

What is Design Therapeutics' stock symbol?

Design Therapeutics trades on the NASDAQ under the ticker symbol "DSGN."

How do I buy shares of Design Therapeutics?

Shares of DSGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Design Therapeutics' stock price today?

One share of DSGN stock can currently be purchased for approximately $14.66.

How much money does Design Therapeutics make?

Design Therapeutics (NASDAQ:DSGN) has a market capitalization of $817.73 million and generates $230,000.00 in revenue each year. The company earns $-35,530,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis.

How many employees does Design Therapeutics have?

Design Therapeutics employs 37 workers across the globe.

How can I contact Design Therapeutics?

Design Therapeutics' mailing address is 6005 HIDDEN VALLEY ROAD SUITE 110, CARLSBAD CA, 92011. The official website for Design Therapeutics is www.designtx.com. The company can be reached via phone at 858-293-4900 or via email at alicia@thrustsc.com.

This page (NASDAQ:DSGN) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.